Neuromelanin synthesis in rat and human substantia nigra

SummaryA relation between neuromelanin synthesis and vulnerability of dopaminergic neurons is suggested by the fact that heavily pigmented cells are preferentially lost in aging and Parkinson's disease and that the dopaminergic neurotoxin MPP+ (1-methyl-4-phenyl-pyridine) binds to neuromelanin. To elucidate the mechanism of neuromelanin synthesis, we studied the formation of melanin in homogenates of human and rat substantia nigra tissue “in vitro”. It was found that enzymatic processes accounted for 70% and 90% of the melanin formation in homogenates of human and rat tissue, respectively. The enzymatic synthesis was due to the activity of monoamine oxidase (MAO), since it was prevented by selective inhibitors of this enzyme. Both MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and MPP+ inhibited melanin formation, probably due to their ability to inhibit MAO. No evidence was found for involvement of cytochrome P-450 monooxigenases, which have been postulated to exist in central catecholaminergic neurons. Proadifen reduced melanin formation, not necessarily because it is an inhibitor of P-450 monooxigenases, but rather as it is also a potent inhibitor of MAO. Some antioxidants like ascorbic acid, but not agents destroying hydrogen peroxide, inhibited melanin formation. The findings suggest that the formation of neuromelanin in the substantia nigra involves MAO and non-enzymatic oxidative processes.

[1]  E. Melamed,et al.  Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP , 1985, Neuropharmacology.

[2]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[3]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[4]  G. Curzon,et al.  MELANIN FORMATION BY HUMAN BRAIN IN VITRO , 1975, Journal of neurochemistry.

[5]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[6]  J. Gustafsson,et al.  Presence of NADPH-cytochrome P450 reductase in central catecholaminergic neurones , 1984, Nature.

[7]  Marsden Cd Neuromelanin and Parkinson's disease. , 1983 .

[8]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[9]  S. Markey,et al.  MPTP-Induced Parkinsonian Syndromes in Humans and Animals , 1986 .

[10]  R. Carelli,et al.  Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion , 1986, Neuropharmacology.

[11]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[12]  W. Lovenberg,et al.  Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. , 1985, European journal of pharmacology.

[13]  R. Katzman.,et al.  NEURONAL PIGMENTS: SPECTROSCOPIC CHARACTERIZATION OF HUMAN BRAIN MELANIN , 1978, Journal of neurochemistry.

[14]  W. Lichtensteiger Effect of electrical stimulation on the fluorescence intensity of catecholamine‐containing tuberal nerve cells * , 1971, The Journal of physiology.

[15]  R. Clavier,et al.  Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse , 1985, Neuroscience Letters.

[16]  B. Parsons,et al.  Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]parygyline binding to monoamine oxidase , 1985, Brain Research.

[17]  D. Graham,et al.  Inhibition of DNA polymerase from L1210 murine leukemia by a sulfhydryl reagent from agaricus bisporus. , 1977, Cancer research.

[18]  D. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[19]  M. Zompo,et al.  1 ‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine: Correspondence of Its Binding Sites to Monoamine Oxidase in Rat Brain, and Inhibition of Dopamine Oxidative Deamination In Vivo and In Vitro , 1985, Journal of neurochemistry.

[20]  R. S. Balgir Serological markers in unipolar and bipolar affective disorders. , 1986, Human heredity.

[21]  G. Prota Recent advances in the chemistry of melanogenesis in mammals. , 1980, The Journal of investigative dermatology.

[22]  B. Parsons,et al.  High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. , 1984, European journal of pharmacology.

[23]  V. Yong,et al.  Monoamine oxidase B, smoking, and Parkinson's disease , 1986, Journal of the Neurological Sciences.

[24]  H. Barden THE HISTOCHEMICAL RELATIONSHIP OF NEUROMELANIN AND LIPOFUSCIN , 1969, Journal of neuropathology and experimental neurology.

[25]  N. Castagnoli,et al.  Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin. , 1986, Life sciences.

[26]  C. Barton,et al.  Neuromelanin and RNA in cells of substantia nigra. , 1977, Journal of neuropathology and experimental neurology.

[27]  R. Lillie METAL REDUCTION REACTIONS OF THE MELANINS: HISTOCHEMICAL STUDIES , 1957, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  U. Bonuccelli,et al.  Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: Binding and biochemical studies , 1986, Brain Research.

[29]  F. Hefti,et al.  A quantitative correlation between single unit activity and fluorescence intensity of dopamine neurones in zona compacta of substantia nigra, as demonstrated under the influence of nicotine and physostigmine , 1976, Brain Research.

[30]  F. Hefti,et al.  Spike activity and histofluorescence correlated in the giant dopamine neuron of Planorbis corneus , 1979, Brain Research.

[31]  R. Fuller,et al.  Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents. , 1985, Life sciences.

[32]  K. Prasad,et al.  SPECTROSCOPIC STUDIES OF SUBSTANTIA NIGRA PIGMENT IN HUMAN SUBJECTS * , 1967, Journal of neurochemistry.

[33]  D. Graham On the origin and significance of neuromelanin. , 1979, Archives of pathology & laboratory medicine.

[34]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[35]  J. Roth,et al.  Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. , 1978, Biochemical pharmacology.

[36]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[37]  R. Fariello,et al.  Neuromelanic pigment in substantia nigra neurons of rats and dogs , 1986, Neuroscience Letters.

[38]  B. Bogerts A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker , 1981, The Journal of comparative neurology.

[39]  P. Yates,et al.  Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. , 1974, Brain : a journal of neurology.

[40]  J. Knoll,et al.  Deprenyl (selegiline): the history of its development and pharmacological action , 1983, Acta neurologica Scandinavica. Supplementum.

[41]  P. Jeffs,et al.  Investigation of structure-function relationships of cytotoxic quinones of natural and synthetic origin. , 1978, Cancer research.

[42]  T. Singer,et al.  Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Biochemical and biophysical research communications.

[43]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[44]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[45]  D. D. Di Monte,et al.  Studies on the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine cytotoxicity in isolated hepatocytes. , 1987, Life sciences.

[46]  S. Snyder,et al.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. , 1986, Neurology.

[47]  M. Grisham,et al.  Neuromelanogenic and Cytotoxic Properties of Canine Brainstem Peroxidase , 1987, Journal of neurochemistry.

[48]  J. Fellman EPINEPHRINE METABOLITES AND PIGMENTATION IN THE CENTRAL NERVOUS SYSTEM IN A CASE OF PHENYLPYRUVIC OLIGOPHRENIA , 1958, Journal of neurology, neurosurgery, and psychiatry.

[49]  G. Fenichel,et al.  Studies on neuromelanin , 1967, Neurology.

[50]  J. Foley,et al.  ON THE NATURE OF PIGMENT GRANULES IN THE CELLS OF THE LOCUS COERULEUS AND SUBSTANTIA NIGRA , 1958, Journal of neuropathology and experimental neurology.

[51]  U. Bondesson,et al.  Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. , 2009, Acta pharmacologica et toxicologica.

[52]  K. Hellmann,et al.  Pigment formation from tryptamine and 5‐hydroxytryptamine in tissues: a contribution to the histochemistry of amine oxidase , 1953, The Journal of physiology.

[53]  S. Pomerantz Separation, purification, and properties of two tyrosinases from hamster melanoma. , 1963, The Journal of biological chemistry.